key: cord-0919576-ywez9giy
authors: Creta, Massimiliano; Sagnelli, Caterina; Celentano, Giuseppe; Napolitano, Luigi; La Rocca, Roberto; Capece, Marco; Califano, Gianluigi; Calogero, Armando; Sica, Antonello; Mangiapia, Francesco; Ciccozzi, Massimo; Fusco, Ferdinando; Mirone, Vincenzo; Sagnelli, Evangelista; Longo, Nicola
title: SARS‐CoV‐2 infection affects the lower urinary tract and male genital system: A systematic review
date: 2021-03-01
journal: J Med Virol
DOI: 10.1002/jmv.26883
sha: 267b2020d674d11e6671bef04c112d8c534dc7d6
doc_id: 919576
cord_uid: ywez9giy

PubMed, Scopus, and ISI Web of Knowledge databases were searched to identify studies published up to December 2020 on the involvement of urinary and male genital systems in COVID‐19. Sixteen studies involving a total of 575 patients (538 males and 37 females) were included in this systematic review. The COVID‐19 phase was available for 479 patients: 426 in the acute and 53 in the recovery phase. De novo lower urinary tract symptoms (LUTS) were observed in 43 patients and deterioration of pre‐existing LUTS in 7. Bladder hemorrhage was observed in three patients and acute urinary retention in one. Regarding the male genital system, scrotal discomfort was observed in 8 patients, swelling in 14, pain in 16, and erythema in 1; low flow priapism was observed in 2 patients. Ultrasound examination identified acute orchitis in 10 patients, acute epididymitis in 7, and acute epididymo‐orchitis in 16. A case–control study reported that patients with moderate COVID‐19 show a significant reduction in sperm concertation, the total number of sperms per ejaculate, progressive motility, and complete motility. In contrast to what is known from the first studies on the subject, this review also includes subsequent studies that give evidence of the involvement of the lower urinary tract and male genital system in COVID‐19.

expanded knowledge on SARS-CoV-2 infection and the associated disease called COVID-19, patients are treated more effectively and most patients recover, the spread of the infection has been contained in many countries, and some vaccines against this virus have become available.

SARS-CoV-2 belongs to the β-coronavirus cluster. 1, 5 Entry of SARS-CoV-2 into host cells depends on cellular expression of both angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2). 1,6-10 Zou et al. analyzed the RNA sequencing datasets of cells of major human physiological systems to evaluate the expression of the ACE2 receptor and constructed a risk map of the different vulnerability of various organs to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 11 This physiological variability is a biological background that may explain the different involvement of individual organs or tissues in the clinical presentation of COVID-19. Evidence has recently emerged that the lower urinary tract is a potential target for SARS-CoV-2 infection, due to a significant ACE2 expression in urothelial cells. 11 ACE2 has also been found in the human testis where it regulates the physiology of Leydig cells, Sertoli cell, and spermatogonia. 12 In addition, Song et al. 13 analyzed epithelial cells of the normal human prostate and found that ACE2 and TMPRSS2 are expressed in 0.32% and 18.65% of epithelial cells, respectively. Therefore, the urinary and male genital system is now regarded as at risk for SARS-CoV-2 infection and potentially responsible for some nonrespiratory symptoms of COVID-19. 7 The signs and symptoms relative to the involvement of the urinary and male genital systems are sometimes vague, and in any case, little known, therefore clinicians should pay particular attention to detecting them in their patients. 14, 15 The purpose of this systematic review is to highlight currently available literature data on the involvement of the urinary and male genital systems in SARS-CoV-2 infection, to offer young specialists in urology and infectious diseases an overview on this topic to better carry out their activity in this new clinical reality and, hopefully, develop the desire to perform in-depth studies and research on the subject.

This analysis was conducted and reported according to the general guidelines recommended by the Primary Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. 16 

A comprehensive literature search was performed using a combination of keywords (MeSH terms and free text words) including "COVID-19"/ "SARS-CoV-2," "Urology"/"Urogenital System," "signs," "symptoms," "laboratory," and "radiology." Three databases (PubMed, Scopus, and ISI Web of Knowledge) were searched for articles published in English up to December 2020. Additional articles were sought from the reference lists of the included studies.

All articles identified from the literature search were screened by two independent reviewers (M. C. and N. L.) with any discrepancies resolved by a third author (C. S.). To assess the eligibility for the systematic review, PICOS (participants, intervention, comparisons, outcomes, study type) criteria were used. PICOS criteria were set as follows: (P)articipants-the subjects infected with SARS-CoV-2; (I) ntervention-the evaluation of signs, symptoms, laboratory or radiological findings relative to the urinary and/or male genital tract; (O) utcome-the evidence of signs and/or symptoms and/or laboratory findings and/or radiological evaluations indicative of male genital and/or urinary tract involvement; (S)tudy types-prospective and retrospective studies, review articles, meta-analysis, case series, case reports, letters to editors; studies related to nephrology, obstetrics, and gynecology were not included.

The following data were extracted from eligible studies: authors,

year of publication, study period, study design, sample size, site of the study, patients' age and gender, disease state (acute vs. recovery), results of rhino-pharyngeal swab, SARS-CoV-2 antibody status, COVID-19 severity, signs and/or symptoms regarding the lower urinary tract or the male genital tract, symptom scores, findings from radiological and/or laboratory investigations regarding the lower urinary tract or the male genital tract, strategies adopted to manage these conditions.

The search strategy revealed a total of 339 results. Screening of the titles and abstracts revealed 25 papers eligible for inclusion. Further assessment of eligibility, based on full-text papers, led to the exclusion of nine papers. Finally, 16 studies involving a total of 575 patients infected with SARS-CoV-2 who had been evaluated for urinary and/or male genital involvement between January and June 2020 were included in the final analysis [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] (Figure 1 ). The characteristics of selected studies are summarized in Table 1 .

Patients' demographics are reported in Table 1 

Urinary tract involvement was reported in five studies ( Table 2) . [26] [27] [28] [29] In detail, de novo lower urinary tract symptoms (LUTS) and deterioration of pre-existing LUTS occurred in 43 and 7 patients, respectively. Validated questionnaires to score LUTS were adopted in two studies. 28, 29 Dhar et al. 28 scored symptoms according to the Overactive Bladder Symptom Score and found a median overactive bladder symptom score of 18 in both men and women. Kaya et al. 29 adopted the International Prostate Symptom Score (IPSS) and the Urinary Symptom Profile (USP) for men and women, respectively and found, both in men and women, a statistically significant worsening in terms of both mean IPSS and mean UPS stress urinary incontinence/ overactive bladder subscores.

Other signs of lower urinary tract involvement were bladder hemorrhage in three patients and acute urinary retention in one. 27 Microhematuria and leukocyturia were reported in three and two patients, respectively. Urine culture was negative in all 45 patients investigated. Radiologic data were not available in these five studies.

Male genital tract involvement was investigated in 11 studies [17] [18] [19] [20] [21] [22] [23] [24] [25] 30, 31 ( Table 3 ). Scrotal discomfort was described in 8 patients, swelling in 14, pain in 16, and erythema in 1. Low flow priapism was reported in 2 patients. 23, 30 Scrotal ultrasound was performed in 4 studies 20-22,24 : acute orchitis was found in 10 patients, acute epididymitis in 7, and acute epididymo-orchitis in 16 20, 22, 24 ; one case of bilateral nonspecific intratesticular increased blood flow was also described. 21 Alkhatatbeh et al. 22 Acute orchitis (3) n/a n/a Acute epididymitis (3) Epididymo-orchitis (5) Chen et al. 20 n/a Scrotal swelling/pain (10) Acute orchitis (7) n/a n/a Acute epididymitis (4) Epididymo-orchitis (10 concertation, the total number of sperms per ejaculate, progressive motility, and complete motility, whereas no statistically significant difference was found between controls and patients with mild disease. 17 Accordingly, Guo et al. 19 found total sperm count, total motile sperm count, and sperm morphology within normal ranges in a population mainly composed of patients with mild COVID-19, tested after a median interval of 32 days from diagnosis.

The Therefore, physicians caring for COVID-19 patients, in ambulatory care, clinical wards, or emergency rooms, should be aware of CAC.

Noteworthily, it has been also underlined that an increase in urinary frequency, in addition to fever, should be considered an important symptom of overlap with urosepsis in the context of the differential diagnosis of COVID- 19. 15 Scrotal discomfort or pain with radiological evidence of inflammatory changes of the testis and/or epididymis is the most fre- Postmortem studies of patients who had died of severe acute respiratory syndrome (SARS) showed the presence of orchitis with histological evidence of immune-mediated inflammatory damage. 36 Alkhatatbeh et al., 31 however, failed to observe any symptoms or signs of orchitis in their series, but the relatively small sample size might have failed to capture a rare complication; in addition, most patients in this study were asymptomatic or had mild-to-moderate symptoms and the authors hypothesized that viral threshold required to cross the blood-testis barrier could be not achieved. 31 The involvement of the male genital system in patients with SARS-CoV-2 infection may theoretically impair fertility. Available evidence demonstrates that although a mild COVID-19 infection is not likely to affect spermatogenesis, semen can be impaired after a moderate infection. 17 However, data about semen analysis performed before the outbreak of the pandemic were not available for patients involved in these studies thus limiting the diagnosis of pre-existing male infertility. 17 Moreover, the long-term effects of SARS-CoV-2 on male reproductive function are lacking. 17 Low flow priapism was observed in two patients with severe COVID-19. 23, 30 Once recognized by health-care professionals, low flow priapism should be treated promptly to prevent immediate and chronic functional complications. 23, 30 The pathogenesis of priapism in patients with COVID-19 has been attributed to thrombotic complications. The reporting of further cases would be of interest to strengthen this evidence. 23, 30 We recognize the limitations of the data published so far on the involvement of the urogenital system by SARS-CoV-2, coming from a few studies, often carried out with low methodological quality, and including few patients, often heterogeneous and with short followup. Furthermore, demographics, epidemiological data, and symptoms were recorded in precoded questionnaires only in a few studies. As a result, available data on the involvement of urologic and male genital systems in COVID-19 are sparse and patchy. However, unlike what emerged during the first wave of the pandemic, we now know that this involvement occurs in 3%-5% of cases with SARS-CoV-2 infection and that in some cases the clinical manifestations are relevant.

The data highlighted in this systematic review demonstrate that patients with COVID-19 may have signs, symptoms, and radiological and laboratory features indicative of involvement of the lower urinary tract and of the male genital system. De novo or worsening LUTS, and testis and/or epididymal discomfort or pain are the most common clinical findings. Moreover, spermatogenesis can be impaired in patients with moderate infection. Current knowledge is therefore sufficient to alert all health-care professionals involved in the management of patients with SARS-CoV-19 infection to focus their attention also on the lower urinary tract and male genital system.

SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19)

The impact of the SARS-CoV-2 infection, with special reference to the hematological setting

Chronic conventional disease-modifying anti-rheumatic drugs masking severe SARS-CoV-2 manifestations in an elderly rheumatic patient

Vanvitelli Covid-group. Clinical presentation of COVID-19: case series and review of the literature

COVID-19 outbreak: an overview

COVID-19 and living donor kidney transplantation in Naples during the pandemic

Management of SARS-CoV-2 pneumonia

Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT)

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection

ACE2 receptor expression in testes: implications in coronavirus disease 2019 pathogenesis

Expression of ACE2, the SARS-CoV-2 receptor, and TMPRSS2 in prostate epithelial cells

COVID-19: importance of the awareness of the clinical syndrome by urologists

Urinary frequency as a possibly overlooked symptom in COVID-19 patients: does SARS-CoV-2 cause viral cystitis?

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

Assessment of SARS-CoV-2 in human semen-a cohort study

No evidence of severe acute respiratory syndrome-coronavirus 2 in semen of males recovering from coronavirus disease 2019

Absence of SARS-CoV-2 in semen of a COVID-19 patient cohort

Ultrasound imaging findings of acute testicular infection in patients with coronavirus disease 2019: a singlecenter-based study in Wuhan China

A coronavirus disease 2019 (COVID-19) patient with bilateral orchitis: a case report

Orchiepididymitis in a boy with COVID-19

Priapism in a patient with coronavirus disease 2019 (COVID-19): a case report

Testicular pain as an unusual presentation of COVID-19: a brief review of SARS-CoV-2 and the testis

Abdominal and testicular pain: an atypical presentation of COVID-19

COVID-19 inflammation results in urine cytokine elevation and causes COVID-19 associated cystitis (CAC)

Urinary frequency as a possible overlooked symptom in COVID-19 patients: does SARS-CoV-2 cause viral cystitis?

De novo urinary symptoms associated with COVID-19: COVID-19-associated cystitis

Could LUTS be early symptoms of COVID-19

A Peculiar case of priapism: the hypercoagulable state in patients with severe COVID-19 infection

Does severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) cause orchitis in patients with coronavirus disease 2019 (COVID-19)?

A systematic review on COVID-19: urological manifestations, viral RNA detection and special considerations in urological conditions

Effects of alpha1-blockers on urodynamic parameters of bladder outlet obstruction in patients with lower urinary tract symptoms suggestive of benign prostatic enlargement: a review

Benign prostatic obstruction relief in patients with lower urinary tract symptoms suggestive of benign prostatic enlargement undergoing endoscopic surgical procedures or therapy with alpha-blockers: a review of urodynamic studies

Urinary viral shedding of COVID-19 and its clinical associations: a systematic review and meta-analysis of observational studies

Orchitis: a complication of severe acute respiratory syndrome (SARS)

SARS-CoV-2 infection affects the lower urinary tract and male genital system: A systematic review